Vetoryl 120mg Capsules for Dogs (pack of 30)
|Prescription Type||POM-V (Written prescription required)|
What is Vetoryl and who is it for?
Vetoryl is a hard capsule that is used for the treatment of pituitary-dependent and adrenal-dependent hyperadrenocorticism (Cushing's disease and syndrome) in dogs.
This is a Prescription only medicine (POM-V).
Vetoryl is only available with a prescription from your veterinary surgeon.
To check the most up to date information about this product, please read its Summary of Product Characteristics (SPC). It can be viewed here.
What is the active ingredient in Vetoryl?
Trilostane selectively and reversibly inhibits the enzyme system 3 beta hydroxysteroid isomerase, thus blocking the production of cortisol, corticosterone and aldosterone.
When used to treat hyperadrenocorticism, it reduces the production of glucocorticoid and mineralocorticoid steroids in the adrenal cortex. Circulating concentrations of these steroids are thus reduced. Trilostane also antagonises the activity of exogenous adrenocorticotrophic hormone (ACTH). It has no direct effect on either the central nervous or cardiovascular systems.
What is in Vetoryl?
Hard capsules. Ivory body and black cap with the capsule strength printed on the body of the capsule.
Each tablet contains:
Trilostane 120 mg
Titanium dioxide (E171) 1.885 mg
Yellow iron oxide (E172) 0.071 mg
Black iron oxide (E172) 1.064 mg
How do I use Vetoryl?
Vetoryl is a prescription product and must be used according to the instructions of your veterinary surgeon.
Please read the product leaflet thoroughly before administering to your pet.
Marketing Authorisation Holder
Snaygill Industrial Estate
Marketing Authorisation Number
Is there any further advice I should know about Vetoryl?
Do not use in dogs weighing less than 20 kg.
Do not use in animals suffering from primary hepatic disease and/or renal insufficiency.
Do not use where there is suspected hypersensitivity to the active substance or to any of the excipients.
Special warnings for each target species
An accurate diagnosis of hyperadrenocorticism is essential.
Where there is no apparent response to treatment, the diagnosis should be re-evaluated. Dose increases may be necessary.
Veterinarians should be aware that dogs with hyperadrenocorticism are at increased risk of pancreatitis. This risk may not diminish following treatment with trilostane.
Special precautions for use in animals
As the majority of cases of hyperadrenocorticism are diagnosed in dogs between the ages of 10-15 years, other pathological processes are frequently present. It is particularly important to screen cases for primary hepatic disease and renal insufficiency as the product is contraindicated in these cases.
Subsequent close monitoring during treatment should be carried out. Particular attention should be paid to liver enzymes, electrolytes, urea and creatinine.
The presence of diabetes mellitus and hyperadrenocorticism together requires specific monitoring.
If a dog has previously been treated with mitotane, its adrenal function will have been reduced. Experience in the field suggests that an interval of at least a month should elapse between cessation of mitotane and the introduction of trilostane. Close monitoring of adrenal function is advised, as dogs may be more susceptible to the effects of trilostane.
The product should be used with extreme caution in dogs with pre-existing anaemia as further reductions in packed-cell volume and haemoglobin may occur. Regular monitoring should be undertaken.
Special precautions to be taken by the person administering the product to animals
Trilostane may decrease testosterone synthesis and has anti-progesterone properties. Women who are pregnant or are intending to become pregnant should avoid handling the capsules.
Wash hands with soap and water following accidental exposure and after use.
The content of the capsules may cause skin and eye irritation and sensitisation. Do not divide or open capsules: in the event of accidental breakage of the capsules and contact of the granules with eyes or skin, wash immediately with plenty of water. If irritation persists, seek medical advice.
People with known hypersensitivity to trilostane or any of the excipients should avoid contact with the product.
In the event of accidental ingestion, seek medical advice immediately and show the package leaflet or carton to the physician.
Corticosteroid withdrawal syndrome or hypocortisolaemia should be distinguished from hypoadrenocorticism by evaluation of serum electrolytes.
Signs associated with iatrogenic hypoadrenocorticism, including weakness, lethargy, anorexia, vomiting and diarrhoea may occur, particularly if monitoring is not adequate (see Amounts to be administered and administration route). Signs are generally reversible within a variable period following withdrawal of treatment. Acute Addisonian crisis (collapse) may also occur (see Overdose). Lethargy, vomiting, diarrhoea and anorexia have been seen in dogs treated with trilostane in the absence of evidence of hypoadrenocorticism.
There have been occasional isolated reports of adrenal necrosis in treated dogs which may result in hypoadrenocorticism.
Subclinical renal dysfunction may be unmasked by treatment with the product.
Treatment may unmask arthritis due to a reduction in endogenous corticosteroid levels.
A small number of reports have been received of sudden death during treatment.
Other mild, rare, adverse effects include ataxia, hypersalivation, bloating, muscle tremors and skin changes.
Use during pregnancy and lactation
Do not use in pregnant or lactating bitches or in any animals intended for breeding.
The possibility of interactions with other medicinal products has not been specifically studied. Given that hyperadrenocorticism tends to occur in older dogs, many will be receiving concurrent medication. In clinical studies, no interactions were observed.
The risk of hyperkalaemia developing should be considered if trilostane is used in conjunction with potassium-sparing diuretics or ACE inhibitors. The concurrent use of such drugs should be subject to a risk/benefit analysis by the veterinary surgeon, as there have been a few reports of deaths (including sudden death) in dogs when treated concurrently with trilostane and an ACE inhibitor.
Overdose may lead to signs of hypoadrenocorticism (lethargy, anorexia, vomiting, diarrhoea, cardiovascular signs, collapse). There were no mortalities following chronic administration at 36mg/kg to healthy dogs, however mortalities may be expected if higher doses are administered to dogs with hyperadrenocorticism.
There is no specific antidote for trilostane. Treatment should be withdrawn and supportive therapy, including corticosteroids, correction of electrolyte imbalances and fluid therapy may be indicated depending on the clinical signs.
In cases of acute overdosage, induction of emesis followed by administration of activated charcoal may be beneficial.
Any iatrogenic adrenocortical insufficiency is usually quickly reversed following cessation of treatment. However in a small percentage of dogs, effects may be prolonged.
Following a one week withdrawal of trilostane treatment, treatment should be reinstated at a reduced dose rate.
Show products for :